{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:00:03Z","timestamp":1789758003555,"version":"4.0.1"},"reference-count":44,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-n998","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:38:23Z","timestamp":1749199103000},"page":"249-257","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: tumour response and immune-related renal vasculitis following cytoreductive nephrectomy"],"prefix":"10.32074","volume":"117","author":[{"given":"Ekta","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Goksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Magi-Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2025,6]]},"reference":[{"key":"10.32074\/1591-951X-N998_ref1","doi-asserted-by":"crossref","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017 Mar 9;3:17009. https:\/\/doi.org\/10.1038\/nrdp.2017.9. PMID: 28276433; PMCID: PMC5936048.","DOI":"10.1038\/nrdp.2017.9"},{"key":"10.32074\/1591-951X-N998_ref2","doi-asserted-by":"crossref","unstructured":"Bukavina L, Bensalah K, Bray F, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022 Nov;82(5):529-542. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.019. Epub 2022 Sep 10. PMID: 36100483.","DOI":"10.1016\/j.eururo.2022.08.019"},{"key":"10.32074\/1591-951X-N998_ref3","unstructured":"GLOBOCAN 2022. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf."},{"key":"10.32074\/1591-951X-N998_ref4","doi-asserted-by":"crossref","unstructured":"Patel HD, Gupta M, Joice GA, et al. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. Eur Urol Oncol. 2019 Jul;2(4):343-348. https:\/\/doi.org\/10.1016\/j.euo.2018.08.023. Epub 2018 Sep 25. PMID: 31277771.","DOI":"10.1016\/j.euo.2018.08.023"},{"key":"10.32074\/1591-951X-N998_ref5","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines), Kidney cancer, Version 2.2025- September 6, 2024. Available at https:\/\/www.nccn.org\/professionals\/physician _ gls\/pdf\/kidney.pdf."},{"key":"10.32074\/1591-951X-N998_ref6","doi-asserted-by":"crossref","unstructured":"M\u00e9jean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-427. https:\/\/doi.org\/10.1056\/NEJMoa1803675. Epub 2018 Jun 3. PMID: 29860937.","DOI":"10.1016\/j.euo.2018.08.002"},{"key":"10.32074\/1591-951X-N998_ref7","doi-asserted-by":"crossref","unstructured":"Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):164-170. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0117. PMID: 30543350; PMCID: PMC6439568.","DOI":"10.1001\/jamaoncol.2019.0117"},{"key":"10.32074\/1591-951X-N998_ref8","doi-asserted-by":"crossref","unstructured":"Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012 May;187(5):1548-54. https:\/\/doi.org\/10.1016\/j.juro.2011.12.075. Epub 2012 Mar 14. PMID: 22425095.","DOI":"10.1016\/j.juro.2011.12.075"},{"key":"10.32074\/1591-951X-N998_ref9","doi-asserted-by":"crossref","unstructured":"Dine J, Gordon R, Shames Y, et al. Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135. https:\/\/doi.org\/10.4103\/apjon.apjon_4_17. PMID: 28503645; PMCID: PMC5412150.","DOI":"10.4103\/apjon.apjon_4_17"},{"key":"10.32074\/1591-951X-N998_ref10","doi-asserted-by":"crossref","unstructured":"Xu LY, Zhao HY, Yu XJ, et al. Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. J Clin Med. 2023 Feb 8;12(4):1349. https:\/\/doi.org\/10.3390\/jcm12041349. PMID: 36835884; PMCID: PMC9964206.","DOI":"10.3390\/jcm12041349"},{"key":"10.32074\/1591-951X-N998_ref11","doi-asserted-by":"crossref","unstructured":"Bor\u00f3wka M, \u0141\u0105cki-Zynzeling S, Nicze M, et al. Adverse Renal Effects of Anticancer Immunotherapy: A Review. Cancers (Basel). 2022 Aug 23;14(17):4086. https:\/\/doi.org\/10.3390\/cancers14174086. PMID: 36077623; PMCID: PMC9454552.","DOI":"10.3390\/cancers14174086"},{"key":"10.32074\/1591-951X-N998_ref12","doi-asserted-by":"crossref","unstructured":"Wanchoo R, Karam S, Uppal NN, et al. Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017;45(2):160-169. https:\/\/doi.org\/10.1159\/000455014. Epub 2017 Jan 12. PMID: 28076863.","DOI":"10.1159\/000455014"},{"key":"10.32074\/1591-951X-N998_ref13","doi-asserted-by":"crossref","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016 Mar;44:51-60. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001. Epub 2016 Feb 6. PMID: 26874776.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"10.32074\/1591-951X-N998_ref14","doi-asserted-by":"crossref","unstructured":"Koks MS, Ocak G, Suelmann BBM, et al. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. PLoS One. 2021 Jun 8;16(6):e0252978. https:\/\/doi.org\/10.1371\/journal.pone.0252978. PMID: 34101756; PMCID: PMC8186792.","DOI":"10.1371\/journal.pone.0252978"},{"key":"10.32074\/1591-951X-N998_ref15","doi-asserted-by":"crossref","unstructured":"Manohar S, Kompotiatis P, Thongprayoon C, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019 Jan 1;34(1):108-117. https:\/\/doi.org\/10.1093\/ndt\/gfy105. PMID: 29762725.","DOI":"10.1093\/ndt\/gfy105"},{"key":"10.32074\/1591-951X-N998_ref16","doi-asserted-by":"crossref","unstructured":"Seethapathy H, Zhao S, Chute DF, et al. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1692-1700. https:\/\/doi.org\/10.2215\/CJN.00990119. Epub 2019 Oct 31. PMID: 31672794; PMCID: PMC6895474.","DOI":"10.2215\/CJN.00990119"},{"key":"10.32074\/1591-951X-N998_ref17","doi-asserted-by":"crossref","unstructured":"Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019 Jan 6;7(1):2. https:\/\/doi.org\/10.1186\/s40425-018-0478-8. PMID: 30612580; PMCID: PMC6322290.","DOI":"10.1186\/s40425-018-0478-8"},{"key":"10.32074\/1591-951X-N998_ref18","doi-asserted-by":"crossref","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018 Sep;37(9):2579-2584. https:\/\/doi.org\/10.1007\/s10067-018-4177-0. Epub 2018 Jun 19. PMID: 29923081.","DOI":"10.1007\/s10067-018-4177-0"},{"key":"10.32074\/1591-951X-N998_ref19","doi-asserted-by":"crossref","unstructured":"Lee CM, Wang M, Rajkumar A, et al. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology. Semin Arthritis Rheum. 2024 Jun;66:152440. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152440. Epub 2024 Mar 27. PMID: 38579593.","DOI":"10.1016\/j.semarthrit.2024.152440"},{"key":"10.32074\/1591-951X-N998_ref20","doi-asserted-by":"crossref","unstructured":"Kishi S, Minato M, Saijo A, et al. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. Intern Med. 2018 May 1;57(9):1259-1263. https:\/\/doi.org\/10.2169\/internalmedicine.9814-17. Epub 2017 Dec 27. PMID: 29279511; PMCID: PMC5980806.","DOI":"10.2169\/internalmedicine.9814-17"},{"key":"10.32074\/1591-951X-N998_ref21","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. https:\/\/doi.org\/10.1002\/art.37715. PMID: 23045170.","DOI":"10.1002\/art.37715"},{"key":"10.32074\/1591-951X-N998_ref22","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016 Jul 29;11(7):e0160221. https:\/\/doi.org\/10.1371\/journal.pone.0160221. PMID: 27472273; PMCID: PMC4966895.","DOI":"10.1371\/journal.pone.0160221"},{"key":"10.32074\/1591-951X-N998_ref23","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens. 2011 May;20(3):263-70. https:\/\/doi.org\/10.1097\/MNH.0b013e3283456731. PMID: 21422922; PMCID: PMC4096782.","DOI":"10.1097\/MNH.0b013e3283456731"},{"key":"10.32074\/1591-951X-N998_ref24","doi-asserted-by":"crossref","unstructured":"Martinez Valenzuela L, Bordignon Draibe J, Fulladosa Oliveras X, et al. T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach. Clin Kidney J. 2019 Apr 19;12(4):503-511. https:\/\/doi.org\/10.1093\/ckj\/sfz029. PMID: 31384441; PMCID: PMC6671423.","DOI":"10.1093\/ckj\/sfz029"},{"key":"10.32074\/1591-951X-N998_ref25","doi-asserted-by":"crossref","unstructured":"Casafont-Sol\u00e9 I, Mart\u00ednez-Morillo M, Camins-F\u00e0bregas J, et al. IgA vasculitis and polymyalgia rheumatica induced by durvalumab. Transl Lung Cancer Res. 2020 Apr;9(2):421-423. https:\/\/doi.org\/10.21037\/tlcr.2020.03.01. PMID: 32420087; PMCID: PMC7225140.","DOI":"10.21037\/tlcr.2020.03.01"},{"key":"10.32074\/1591-951X-N998_ref26","doi-asserted-by":"crossref","unstructured":"Aqeel F, Monroy-Trujillo J, Geetha D. Immune checkpoint inhibitors as potential triggers for ANCA vasculitis. RMD Open. 2022 Aug;8(2):e002500. https:\/\/doi.org\/10.1136\/rmdopen-2022-002500. PMID: 35922081; PMCID: PMC9353042.","DOI":"10.1136\/rmdopen-2022-002500"},{"key":"10.32074\/1591-951X-N998_ref27","doi-asserted-by":"crossref","unstructured":"Hung W, Cusnir I, Habib S, et al. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis. Rheumatology (Oxford). 2021 Jun 18;60(6):e190-e191. https:\/\/doi.org\/10.1093\/rheumatology\/keaa818. PMID: 33367837.","DOI":"10.1093\/rheumatology\/keaa818"},{"key":"10.32074\/1591-951X-N998_ref28","doi-asserted-by":"crossref","unstructured":"Laamech R, Terrec F, Emprou C, et al. Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion. Case Rep Nephrol Dial. 2021 Dec 30;11(3):376-383. https:\/\/doi.org\/10.1159\/000518304. PMID: 35111820; PMCID: PMC8787507.","DOI":"10.1159\/000518304"},{"key":"10.32074\/1591-951X-N998_ref29","doi-asserted-by":"crossref","unstructured":"Belkaid S, Berger M, Nouvier M, et al. A case of Sch\u00f6nlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma. Eur J Cancer. 2020 Nov;139:169-172. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.005. Epub 2020 Sep 29. PMID: 32992155.","DOI":"10.1016\/j.ejca.2020.08.005"},{"key":"10.32074\/1591-951X-N998_ref30","doi-asserted-by":"crossref","unstructured":"Ishimura N, Shiotsu Y, Masuzawa N, et al. Renal granulomatous arteritis induced by immune checkpoint inhibitors. Kidney Int. 2020 Sep;98(3):793. https:\/\/doi.org\/10.1016\/j.kint.2020.03.008. PMID: 3282824.","DOI":"10.1016\/j.kint.2020.03.008"},{"key":"10.32074\/1591-951X-N998_ref31","doi-asserted-by":"crossref","unstructured":"Person F, Chahoud-Schriefer T, Fehrle W, et al. Severe Acute Kidney Injury Due to Nivolumab\/Ipilimumab-induced Granulomatosis and Fibrinoid Vascular Necrosis. J Immunother. 2020 Jan;43(1):29-31. https:\/\/doi.org\/10.1097\/CJI.0000000000000296. PMID: 31567702.","DOI":"10.1097\/CJI.0000000000000296"},{"key":"10.32074\/1591-951X-N998_ref32","doi-asserted-by":"crossref","unstructured":"Gallan AJ, Alexander E, Reid P, et al. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors. Am J Kidney Dis. 2019 Dec;74(6):853-856. https:\/\/doi.org\/10.1053\/j.ajkd.2019.04.016. Epub 2019 Jun 14. PMID: 31204194.","DOI":"10.1053\/j.ajkd.2019.04.016"},{"key":"10.32074\/1591-951X-N998_ref33","doi-asserted-by":"crossref","unstructured":"Lemoine M, Dilly B, Curie A, et al. Ipilimumab-induced renal granulomatous arteritis: a case report. BMC Nephrol. 2019 Oct 11;20(1):366. https:\/\/doi.org\/10.1186\/s12882-019-1552-2. PMID: 31604452; PMCID: PMC6788031.","DOI":"10.1186\/s12882-019-1552-2"},{"key":"10.32074\/1591-951X-N998_ref34","doi-asserted-by":"crossref","unstructured":"Mamlouk O, Lin JS, Abdelrahim M, et al. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer. 2020 Jul;8(2):e000750. https:\/\/doi.org\/10.1136\/jitc-2020-000750. PMID: 32718987; PMCID: PMC7380836.","DOI":"10.1136\/jitc-2020-000750"},{"key":"10.32074\/1591-951X-N998_ref35","doi-asserted-by":"crossref","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 Sep;90(3):638-47. https:\/\/doi.org\/10.1016\/j.kint.2016.04.008. Epub 2016 Jun 7. PMID: 27282937; PMCID: PMC4983464.","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"10.32074\/1591-951X-N998_ref36","doi-asserted-by":"crossref","unstructured":"Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer. 2017 Mar-Apr;41(2):100-110. https:\/\/doi.org\/10.1016\/j.currproblcancer.2016.12.004. Epub 2016 Dec 19. PMID: 28189263; PMCID: PMC5440194.","DOI":"10.1016\/j.currproblcancer.2016.12.004"},{"key":"10.32074\/1591-951X-N998_ref37","doi-asserted-by":"crossref","unstructured":"Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E970-E979. https:\/\/doi.org\/10.1073\/pnas.1616848114. Epub 2017 Jan 23. PMID: 28115719; PMCID: PMC5307483.","DOI":"10.1073\/pnas.1616848114"},{"key":"10.32074\/1591-951X-N998_ref38","doi-asserted-by":"crossref","unstructured":"Gupta S, Short SAP, Sise ME, et al. ICPi-AKI Consortium Investigators. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 Oct;9(10):e003467. https:\/\/doi.org\/10.1136\/jitc-2021-003467. Erratum in: J Immunother Cancer. 2023 Apr;11(4):e003467corr1. https:\/\/doi.org\/10.1136\/jitc-2021-003467corr1. PMID: 34625513; PMCID: PMC8496384.","DOI":"10.1136\/jitc-2021-003467corr1"},{"key":"10.32074\/1591-951X-N998_ref39","doi-asserted-by":"crossref","unstructured":"Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1\/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol. 2018 Mar;103(3):565-575. https:\/\/doi.org\/10.1189\/jlb.3MA0717-283. Epub 2017 Dec 29. PMID: 28848042; PMCID: PMC6457250.","DOI":"10.1189\/jlb.3MA0717-283"},{"key":"10.32074\/1591-951X-N998_ref40","doi-asserted-by":"crossref","unstructured":"Panian J, Saidian A, Hakimi K, et al. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. Oncologist. 2024 Oct 3;29(10):870-877. https:\/\/doi.org\/10.1093\/oncolo\/oyad166. PMID: 37368355; PMCID: PMC11448883.","DOI":"10.1093\/oncolo\/oyad166"},{"key":"10.32074\/1591-951X-N998_ref41","doi-asserted-by":"crossref","unstructured":"Gunenc D, Issa W, Gerald T, et al. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN). Clin Genitourin Cancer. 2024 Oct;22(5):102177. https:\/\/doi.org\/10.1016\/j.clgc.2024.102177. Epub 2024 Jul 23. PMID: 39218752.","DOI":"10.1016\/j.clgc.2024.102177"},{"key":"10.32074\/1591-951X-N998_ref42","doi-asserted-by":"crossref","unstructured":"Pichler R, Comp\u00e9rat E, Klatte T, et al. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel). 2019 Mar 25;11(3):422. https:\/\/doi.org\/10.3390\/cancers11030422. PMID: 30934624; PMCID: PMC6468799.","DOI":"10.3390\/cancers11030422"},{"key":"10.32074\/1591-951X-N998_ref43","doi-asserted-by":"crossref","unstructured":"Iacovelli R, Ciccarese C, Bria E, et al. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020 Sep;136:195-203. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.008. Epub 2020 Jul 23. PMID: 32712550.","DOI":"10.1016\/j.ejca.2020.06.008"},{"key":"10.32074\/1591-951X-N998_ref44","doi-asserted-by":"crossref","unstructured":"Singla N, Elias R, Ghandour RA, et al. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urol Oncol. 2019 Dec;37(12):924-931. https:\/\/doi.org\/10.1016\/j.urolonc.2019.08.012. Epub 2019 Sep 12. PMID: 31522865; PMCID: PMC9489229.","DOI":"10.1016\/j.urolonc.2019.08.012"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:39:14Z","timestamp":1751978354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-n998","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"6"}}